Hoffmann-La Roche: Cytomegalovirus Infections trials

The registry lists 20 Cytomegalovirus Infections studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 3Phase 2 2Phase 3 3Phase 4 3No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant RecipientsCompletedNCT02062294Results posted
• A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched ControlsCompletedNCT01663740Phase 4Results posted
• A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant RecipientsCompletedNCT01376804Phase 4Results posted
• A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.CompletedNCT00377741Phase 1Results posted
• A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal TransplantationCompletedNCT00372229Phase 3Results posted
• IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft RecipientsCompletedNCT00294515Phase 3Results posted
• A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant RecipientsCompletedNCT00090766Phase 2/3Results posted
• A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft RecipientsCompletedNCT01753167Phase 2
• A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of AgeCompletedNCT01165580Phase 1
• VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant RecipientsCompletedNCT00431353Phase 4
• The Safety and Effectiveness of Ganciclovir Plus Interferon Beta in Preventing the Return of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSCompletedNCT00002299Not applicable
• A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDSCompletedNCT00002273Not applicable
• A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDSCompletedNCT00002257Not applicable
• A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral GanciclovirCompletedNCT00002251Not applicable
• A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir TherapyCompletedNCT00002247Not applicable
• A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and DidanosineCompletedNCT00002096Phase 1
• A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency VirusCompletedNCT00002095Not applicable
• A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDSCompletedNCT00002034Not applicable
• Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised PatientCompletedNCT00002025Not applicable
• Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus InfectionsCompletedNCT00002024Not applicable